TARRYTOWN, N.Y. and PARIS, Feb. 22, 2021
Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics frequently underrepresented in advanced NSCLC trials
This is the third approval for Libtayo in the U.S.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) for the first
Let's Bend the Rules for All the Right Reasons
By: Amanda Nerstad
This pandemic has been hard on everyone. Covid-19 is scary to me, especially as a stage IV lung cancer patient. I have followed all of the rules. I mask up when I go out, I choose to stay home as much as I can, I’m not visiting other homes, our family is not taking visitors in our home, we use grocery delivery services and we do our best to keep everyone healthy.
I’ve had to explain to my daughters
THURSDAY, Oct. 1, 2020 (HealthDay News) -- A newly approved drug for the leading form of the number one cancer killer, lung cancer, does improve patient survival, a new study confirms.
The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diag
8/20/2020, Online ahead of print.
Background: Among all cancers, lung cancer has high mortality among patients in most of countries in the world. Targeting delivery of anticancer drugs can significantly reduce the side effects and dramatically improve the treating effect. Folate, which is one suitable ligand, can be modified to the surface of tumor-selective drug delivery systems. Because it can selectively bind to the folate rece
Sunday, July 26, 2020
Histological subtyping of lung cancer is still clinically important, said Ignacio I. Wistuba, MD. However, additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.
The diagnostic algorithm for lung can
By EH News Bureau On Jul 17, 2020
Researchers at Scotland-based University of Dundee have demonstrated a new method of destroying an ‘undruggable’ protein known to play a role in cancer, raising the possibility of a new therapeutic approach to the disease.
Mutations of the K-Ras protein have long been known to cause many cancers, including lung, colorecta
July 07, 2020
Individuals with a smoking history should begin annual screening for lung cancer at age 50 years instead of age 55 years, according to a draft recommendation issued by the U.S. Preventive Services Task Force.
The recommendation, an update of USPSTF guidance on lung cancer screening issued 7 years ago, also reduces smoking pack-year elig
By Nicole Viviano
June 25, 2020
Biking across the United States is a memorable feat for anyone. One endurance athlete from Lawrenceville managed to complete the Southern Tier bike route while facing down an even greater obstacle: Stage 4 lung cancer.
Isabella de la Houssaye, 56, has lived an active lifestyle, from mountain climbing to Ironman triathlons. Her love of
Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer.
JUNE 16, 2020
The significant and clinically meaningful improvement in disease-free survival (DFS) demonstrated with adjuvant osimertinib (Tagrisso) in patients with EGFR-mutated, stage I, II, an
Original article post on Jun 09, 2020 on Precision Oncology News
NEW YORK – Revolution Medicines announced today that it has dosed the first patient in a Phase Ib clinical trial evaluating its investigational SHP2 inhibitor, RMC-4630, in combination with Amgen's KRAS G12C inhibitor AMG510.
The open-label, dose escalation and expansion study, sponsored and conducted by Amgen, is evaluating the combination in patients with advanced solid tumors characterized by KRAS G12C mutations. Revol
AI can categorize lung nodules' cancer risk, study suggests
A new artificial intelligence algorithm can accurately assess the risk of cancer associated with indeterminate pulmonary nodules in patients' lungs, according to a study published in American Journal of Respiratory and Critical Care Medicine.
Traditionally, physicians use CT scans to assess lung nodules, which can lead to earlier cancer diagnoses. However, this approach can also lead to overtreatment if nodule
By Kim Polacek, APR, CPRC - April 27, 2020
An immunotherapy that has demonstrated durable responses in patients with melanoma is now showing promise for those with non-small cell lung cancer. Tumor infiltrating lymphocyte therapy, or “TIL,” uses a patient’s own live immune cells to fight cancer. Surgeons remove a patient’s tumor and, in the lab, dissect and culture the T cells inside. These cells, which were able to detect and invade the tumor, are then multiplied by the billions — a
Liquid biopsies are easier on patients, yield faster results and cost less than tissue biopsies, but these blood draws don’t yet replace traditional tests.
BY MEERI KIM, PH.D.
PUBLISHED APRIL 20, 2020
During winter 2013, Larry Gershon had a bad cold that he couldn’t shake. The then 65-year-old print broker took cold medicine and steroids to fight off the symptom
Given recent findings that cancer patients may be at higher risk of contracting the new coronavirus if they visit medical centers, the Lung Cancer Foundation of America (LCFA) has issued a work-in-progress advisory for lung cancer patients and their doctors on how to navigate cancer treatment during the pandemic.
The guidance is specific to people with non-small-cell lung cancer (NSCLC), which accou
With everyone on edge during the coronavirus pandemic, I wanted to share this story of a lung cancer survivor who has fully recovered from the virus.
Man who lost lung battling cancer survives coronavirus decade later
BEAVER COUNTY, Pa. — A Pennsylvania man who lost a lung to cancer about a decade ago has survived another health battle -- this time, with the coronavirus.
It started as what he assumed was just a cold, but when Richard Botti, 61,